Johnson Pharmacare Limited , a pharmaceutical company, has announced a significant change in its board composition. The company's Board of Directors has accepted the resignation of Mr. Paresh Sengal from his position as Director, effective October 27, 2025.

Resignation Details

Mr. Sengal cited preoccupation with other work as the reason for his departure. In his resignation letter, he expressed gratitude to his fellow board members for their cooperation during his tenure as Director.

Board Meeting Particulars

The decision was made during a board meeting held at the company's registered office. Here are the key details of the meeting:

Company Information

Johnson Pharmacare Limited, formerly known as Sun and Shine Worldwide Limited, is listed on the BSE with the following details:

The company's registered office is located at the Regus Business Centre, Privilon, East Wing, 2nd Floor, Sarkhej Gandhinagar Highway, Bodakdev, Ahmedabad, Gujarat, India - 380054.

This board change comes as part of the company's ongoing corporate governance processes. The company has duly informed the BSE about this development, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Investors and stakeholders are advised to take note of this change in the company's leadership structure.

Johnson Pharmacare Limited, a pharmaceutical company, has reported a wider net loss for the first quarter of the fiscal year 2026, according to the company's latest financial results.

Financial Performance

The company's unaudited financial results for the quarter ended June 30, 2025, reveal:

Johnson Pharmacare reported a net loss of Rs. 5.34 lacs for the quarter, compared to a loss of Rs. 3.99 lacs in the same quarter of the previous year. The company did not generate any revenue during this period, continuing a trend observed in recent quarters.

Expense Analysis

The company's total expenses increased significantly:

• Total expenses rose to Rs. 5.34 lacs from Rs. 3.99 lacs year-over-year.
• Other expenses, a major component, increased to Rs. 5.04 lacs from Rs. 3.99 lacs in the previous year's quarter.
• Employee benefit expenses stood at Rs. 0.30 lacs for the quarter.

Capital Structure

Johnson Pharmacare's paid-up equity share capital remains unchanged at Rs. 5,500 lacs, with a face value of Rs. 1 per share. The earnings per share (EPS) for the quarter stood at (0.00), reflecting the company's loss-making position.

Board Meeting and Audit Review

The Board of Directors approved these unaudited financial results in a meeting held on July 23, 2025. The meeting, which took place at the company's registered office in Ahmedabad, commenced at 1:15 PM and concluded at 1:40 PM.

The financial results have been reviewed by the Audit Committee and have undergone a limited review by the company's statutory auditors, Rishi Sekhri and Associates, Chartered Accountants.

Outlook

While the company continues to face challenges with no operational revenue and increasing expenses, it maintains compliance with regulatory requirements. The management has not provided any forward-looking statements or guidance on future performance in the released financial information.

Investors and stakeholders may look for updates on the company's strategies to generate revenue and manage expenses in future communications from Johnson Pharmacare Limited.